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Polycystic kidney disease: Primary extracellular matrix
abnormality or defective cellular differentiation?
JAMES P. CALVET
Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas, USA
Polycystic kidney disease: Primary extracellular matrix abnormality or
defective cellular differentiation? Polycystic kidney disease (PKD) is
inherited as a dominant or recessive trait or can be provoked by
environmental factors. The disease is characterized by the growth of
large epithelial-lined cysts derived from the nephrons and collecting
ducts of affected kidneys. Cysts are thought to initiate as small dilations
in renal tubules, which then expand into fluid-filled cavities of relatively
large size. Cyst formation appears to involve increased cell prolifera-
tion, reversal of tubular epithelial polarity, and epithelial fluid secretion.
In addition, a number of pronounced extracellular matrix changes have
been found in the cystic kidneys of several animal models and in human
autosomal dominant PKD. These abnormalities include thickened,
laminated basement membrane, increased expression of aI type IV
collagen and laminins Bl and B2, and changes in heparan sulfate
proteoglycan and fibronectin. Some of these changes can also be seen in
vitro, reflecting intrinsic abnormalities, and may be associated with
abnormal tubular morphogenesis early in cyst formation as well as later
in cyst expansion. We have been investigating gene expression in the
C57BL/6J-cpk mouse, which has an autosomal recessive form of PKD,
to determine the genetic basis of the abnormal tubule cell growth and
morphology manifested during cyst formation. The expression of the
proto-oncogenes c-fos, c-myc, and c-Ki-ras is elevated early in the
disease process and becomes markedly elevated late in the disease
during the most severe stage of cyst development; the elevated c-fos
expression in vivo is reflected by hypersensitivity to serum stimulation
in vitro, indicating that a basic change has taken place in cystic cells in
vivo which persists in cell culture. The preproEGF gene, which
normally increases expression during postnatal renal development, is
not significantly expressed in cystic kidneys. In contrast, the SGP-2
gene, which is expressed early in nephrogenesis and declines in
maturing collecting ducts, shows increasing expression in cystic kid-
neys. Our results indicate that a number of developmentally regulated
genes are abnormally expressed in PKD, suggesting that the disease is
caused by defective differentiation of kidney tubules.'
Polycystic kidney disease (PKD) is a heterogeneous group of
disorders characterized by the growth of large epithelial-lined
cysts from the nephrons and collecting ducts of affected kidneys
[1, 2]. The human PKDs can be genetically transmitted as either
an autosomal dominant trait (ADPKD) [3] or an autosomal
recessive trait (ARPKD) [4], or can result from xenobiotic
'Abbreviations are: Polycystic kidney disease (PKD); autosomal
dominant PKD (ADPKD); autosomal recessive PKD (ARPKD); diphe-
nylthiazole (DPT); nordihydroguaiaretic acid (NDGA); basement mem-
brane (BM); extracellular matrix (ECM); tubular BM (TBM); proteo-
glycan (PG); heparan sulfate proteoglycan (HS-PG); sulfated
glycoprotein-2 (SGP-2).
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insult (acquired PKD) [5].ADPKD is a common disease, with a
gene frequency of 1 in 500 to 1,000 individuals, and gives rise to
approximately 10% of all end-stage kidney disease. Acquired
PKD arises in over 50% of long-term dialysis patients and is
frequently associated with the development of adenocarcinoma
[6]. At least two genes are associated with ADPKD. PKD1,
which causes the more prevalent form of the disease, has been
localized to the short arm of chromosome 16. Genes for a less
common, unlinked ADPKD (PKD2) and for ARPKD have not
yet been mapped [3, 7].
Cysts are thought to initiate as small dilations in renal
tubules, which then expand into fluid-filled cavities of relatively
large size [1, 2]. Components of cyst formation include epithe-
hal cell proliferation, basement membrane remodeling, and fluid
secretion [7—9]. Cysts enlarge by means of abnormal epithelial
growth, forming what is essentially a fluid-filled tumor [10].
Thus, cystic epithelial cells undergo a transition in their pheno-
typic state, and yet also retain many basic epithelial character-
istics. Cyst enlargement leads to disruption of the normal renal
parenchyma, which interferes with glomerular filtration and
vascular blood flow, ultimately causing renal failure [1, 2].
Animal and cell culture models
A number of animal models have provided insights into the
pathogenesis of PKD [11]. These include two autosomal-reces-
sive murine models, the C57BLI6J-cpk mouse and the DBA/2-
pcy mouse. In addition, there is a recessive porcine model [121.
The C57BL/6J-cpk mouse has a form of polycystic kidney
disease that resembles the rapidly-progressive human ARPKD
[13]. Cysts are initially observed as small proximal tubule
dilations in late fetal and early postnatal cpk mice; however, the
disease rapidly progresses to the collecting ducts shortly after
birth. By two weeks the kidney is significantly enlarged and by
three weeks most of the kidney is overwhelmed by expansive
collecting duct cyst growth. The DBA/2-pcy mouse also has a
recessive PKD. However, in contrast to that in the cpk mouse,
the pcy disease resembles human ADPKD by being slowly
progressive, involving all nephron segments, and by having
similar extrarenal manifestations [14]. The pcy and cpk defects
have been mapped to mouse chromosomes 9 and 12, respec-
tively [14, 15], and therefore represent different genes (with
neither being likely to correspond to the human ADPKD lesion
on chromosome 16).
Recently, an autosomal-dominant rat model of PKD has been
characterized [11, 161. This Han:SPRD-cy rat displays slowly
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progressive disease in heterozygous animals, with similarity to
human ADPKD, and rapidly progressive disease in homozy-
gous animals, with similarity to human ARPKD; this gene locus
has not yet been mapped. Thus, there are both dominant
(homozygous cy rat) and recessive (cpk mouse) models showing
similarity to human ARPKD and both dominant (heterozygous
cy rat) and recessive (pcy mouse) models showing similarity to
human ADPKD. In addition, several transgenic mouse lines
have been developed that also manifest renal cystic disease
[17—191. The transgenes include the c-myc proto-oncogene and
the SV4O Large T antigen gene, which have immortalizing and
transforming activity, respectively. More recently, expression
of a TGFa transgene has been shown to cause renal cysts [20].
Polycystic kidney disease can also be caused by the cystogenic
chemicals diphenylthiazole (DPT) [21] and nordihydroguai-
aretic acid (NDGA) [221 in rats, or by corticosteroids [23] in
rabbits. It is evident, therefore, that cysts can arise by a number
of mechanisms, including spontaneous mutation, transgenes,
and extrinsic chemicals.
A number of cell culture systems have been developed, either
from cystic epithelial cells or from non-cystic kidney cells, as
model systems to study cyst growth in vitro. These include cpk
cystic organ culture [24] and primary epithelial cell culture [25],
porcine polycystic primary epithelial cell culture [12], and
ADPKD primary epithelial cell culture [26]. These culture
systems are being used to investigate the responses of cystic
cells to growth factors and matrix and to identify unique
phenotypic markers specific to cystic cells. Abnormalities in
basement membrane and extracellular matrix expression have
been noted in some of these cell culture systems. Cyst growth
in hydrated collagen gels, using Madin-Darby canine kidney
(MDCK), normal human kidney, and ADPKD cells, has iden-
tified cyst-initiating and cyst-promoting factors [27].
Basement membrane abnormalities in cystic kidneys
It is unmistakably evident from the gross morphology of
polycystic kidneys that cyst growth involves significant base-
ment membrane remodeling. In fact, one of the prevailing
hypotheses for the etiology of PKD is that the primary defect
lies in a basement membrane (BM) or extracellular matrix
(ECM) component [7—11, 28]. This idea is based, in part, on the
multi-organ involvement of PKD, which can include cysts in the
liver and pancreas, intestinal diverticula, aortic and cranial
aneurysms, and cardiac valvular defects, all which have BMI
ECM in common. Furthermore, a defect in a structural extra-
cellular matrix protein, as in osteogenesis imperfecta, Ehiers-
Danlos syndrome, and Marfan's syndrome, would be consistent
with the dominant expression of certain PKD mutations.
The most obvious and convincing ECM abnormality is a
thickening of the basement membrane. However, even this
abnormality is difficult to generalize to all forms of PKD.
Basement membrane thickening was first noted in the DPTrat
model [29] and was then documented in pathological specimens
of human ADPKD kidneys [30], and later confirmed in biopsy
specimens from kidneys of young affected ADPKD patients
[31]. The tubular BM (TBM) thickening was reported in these
studies to be highly variable, with no consistently observed
ultrastructural defect. This was in contrast to duplication of
glomerular basement membrane, which appeared to be a spe-
cific finding in early ADPKD [32]. Cystic basement membrane
Fig. 1. Basement membrane thickening in kidney cysts of the Han:
SPRD-cy rat. PAS-stained cystic kidney from an 8-week-old heterozy-
gous cyl+ rat showing markedly thickened basement membrane (thick
arrows) under atypical, less-differentiated cystic epithelial cells and
morphologically normal basement membrane (thin arrows) under nor-
mal-appearing epithelial cells within the same cyst. The large cyst (top
right) also shows both thick and thin basement membrane regions. Data
furnished by Drs. V.H. Gattone and B.D. Cowley.
can be thin and electron dense or greatly thickened, with a less
dense, fibrillar texture, or with a multilayered, laminated ap-
pearance [26, 30, 311.
Basement membrane abnormalities are evident in some of the
earliest cysts, as has been seen in some proximal tubular
dilations of the newborn cpk mouse kidney [13] and in the
two-week heterozygous cy rat (V.H. Gattone, unpublished
observations). The chemically-induced cyst models have shown
a temporal correlation between cyst induction and basement
membrane thickening, In the DPT-treated rat, for example,
there is progressive thickening, splitting and lamination of the
basement membranes as cysts enlarge in the presence of the
chemical, which then undergo reversal upon withdrawal of the
DPT [33, 34]. In the corticosteroid-treated rabbit, there is a
similar progression of cystic change in conjunction with thick-
ening, folding, focal duplications, and multilayering of the
basement membrane, which reverse as the cysts regress [23].
Of interest is that some cysts in the cy rat show thickened
basement membrane underlying regions having more rounded,
atypical (less differentiated) cells, while other regions within the
same cyst have normal-appearing basement membrane associ-
ated with a normal-appearing (albeit cystic) epithelium (Fig. 1).
Despite the association between basement membrane thick-
ening and cyst formation, there is not necessarily a strict
correlation. For example, thickened basement membrane can
be seen in normal-appearing tubules in cystic kidneys [14].
While the argument can be made that these normal-appearing
tubules with thickened basement membranes are cysts at the
earliest stage of formation, this issue cannot be addressed in
any straightforward manner in the genetic models of PKD.
Basement membrane thickening per se is not sufficient to cause
cyst formation, because it is also seen in a number of non-cystic
pathological situations, such as nephronophthisis, arteriolar
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nephrosclerosis, and diabetes. Furthermore, there can also be
an absence of a morphological basement membrane abnormal-
ity in frank cysts. For example, while thickened, layered
basement membranes have been seen in collecting duct cysts of
the pcy mouse [14], it is very difficult to find microscopically
visible basement membrane changes in the large collecting duct
cysts which dominate the cpk cystic kidney late in disease
progression [3].
In 1974, a tubular basement membrane abnormality was
proposed on theoretical grounds to be the primary defect in
PKD, based on the idea that tubular dilation could result from
a loss of basement membrane tensile strength or to increased
elasticity [35]. However, when basement membrane elasticity
was measured directly by physical viscoelastic tests, it was
determined that normal and cystic basement membranes were
equally compliant [36]. It is now believed that compositional
changes in cystic basement membrane may affect cell-matrix
interactions and consequently the cellular growth characteris-
tics of tubular cells, or may encourage abnormal tubular mor-
phogenesis, leading tubules to become cystic. In support of this
latter idea is the fact that a number of biochemical changes have
now been documented in cystic basement membrane; however,
again there does not appear to be a clear pattern of abnormal-
ities or a consensus of opinion.
Because of the relatively rapid increase in basement mem-
brane thickening associated with cyst development in the DPT
rat (and the relatively rapid regression upon withdrawal of the
chemical), changes in the synthesis or turnover of collagen are
not likely to be involved in the formation of cystic basement
membranes [33]. This was confirmed by amino acid analysis,
which showed only slight increases in the amounts of glycine,
hydroxyproline, and hydroxylysine, suggesting that there are
only small increases in the collagen content of cystic kidneys
[37]. Furthermore, there was no change detected by gel elec-
trophoresis in the amount of type IV collagen [37], and only
slight, focal increases in anti-collagen IV and laminin immuno-
staining in cystic basement membrane [38]. These changes were
in proportion with the basement membrane thickening and did
not seem to reflect an increased concentration of these proteins.
These results (no real change in the collagen composition) are
consistent with the apparently equal distensibility of normal
TBM and cystic BM.
In the cpk mouse, collagen IV and laminin immunostaining
were found to be normal in early cysts and decreased focally in
more advanced cysts [39], although in another report, no
evidence for changes in laminin, flbronectin, or entactin were
found in cystic cpk proximal tubules [40]. Furthermore, the
expression of the a! type IV collagen gene, and the B! and B2
laminin genes, rather than decreasing, showed increases rela-
tive to normal kidneys during the course of cystic disease [39],
possibly to keep pace with the expanding cysts. Curiously,
localization of this collagen IV mRNA by in situ hybridization
showed labeling over the subadjacent interstitial cells rather
than the cystic epithelium, demonstrating expression of type IV
collagen by a cell type not usually associated with basement
membrane synthesis [39]. Nevertheless, primary epithelial cul-
tures of cpk kidneys showed increased incorporation of 35S-
methionine into collagen IV (approximately twofold) and into
laminin (variable; average approximately 5.5-fold) [25]. In hu-
man ADPKD kidneys, there is increased collagen IV mRNA
levels, particularly at end-stage [9]. In the pcy mouse, laminin
and collagen IV mRNA levels are somewhat increased in the
early stages and more significantly elevated in the latter stages
of the disease (P.D. Killen, J.P. Calvet, V.H. Gattone, unpub-
lished observations). It seems, therefore, that a change in
basement membrane collagen synthesis may not be a major
factor in the initiation of cysts; the change is small and does not
occur uniformly in early cyst formation. This altered gene
expression may reflect a less-differentiated cystic epithelium.
Furthermore, changes in gene expression are more significant
only at end-stage and therefore may be due to a late-stage
compensatory response of the kidney to repair its tubular
morphology.
A number of histological studies have reported increases in
fibronectin in the DPT rat and in human ADPKD [38] and in the
corticoid-treated rabbit [23]. Other studies in the DPT rat have
shown significantly decreased ruthenium red staining (sulfated
proteoglycans) specifically in cystic basement membrane, and a
generalized decrease in alcian blue staining (non-specific glyco-
proteins) in both cystic and normal basement membrane in
cystic kidneys, in association with increased basement mem-
brane thickening [33, 38]. In more advanced cystic kidneys in
the DPT rat there was an absence of ruthenium red staining, and
in end-stage human ADPKD kidneys there was variable stain-
ing with prominent focal loss. The decrease of these histochem-
ical markers suggests that there is a specific decrease in heparan
sulfate proteoglycan (HS-PG) and other sulfated glycoproteins
in cystic basement membrane. In another study in the rat, in
which the Phenol II derivative of DPT was used, the loss of
ruthenium red staining occurred in tandem with cyst develop-
ment and basement membrane thickening; however, there was
no loss of alcian blue staining, suggesting that the basement
membrane defect preferentially affects the sulfated PGs [34].
Sulfated proteoglycan synthesis was investigated in labeling
studies using organ cultures from untreated and DPT-treated rat
kidneys perfused with 5S-sulfate [41]. While there was a
significant decrease in 35S incorporation into proteoglycans and
into the TBM fraction, there was a larger decrease in the
labeling of the cellular fraction, suggesting that overall protein
synthesis was significantly decreased and therefore responsible
for the decreased labeling of the PG fraction. In cultures of
porcine polycystic cells there was an approximately 35% reduc-
tion in total 35S incorporation, compared to normal cells [12],
and in cultures of ADPKD cells there was a two- to threefold
reduction [42].
In contrast to the decreased ruthenium red staining seen in
the cystic basement membrane of the DPT rat, Ojeda et al [23]
showed increased staining in the cystic basement membrane of
corticoid-treated rabbit kidneys. This increased ruthenium red
staining is suggestive of an increased HS-PG deposition in the
thickened basement membrane. The different results obtained
with the DPT-treated rat and glucocorticoid-treated rabbit
models could be due to the fact that different chemicals were
used and therefore to two different modes of cyst induction.
However, since they both ultimately lead to cyst formation,
these contrasting results would argue that changes in the PG
composition of cystic basement membranes may be secondary
to the cyst-inducing mechanism. In another study, Wilson et al
[26] showed irregular deposition of ruthenium red-stained ma-
terial along the basal surface of culture cells from ADPKD
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cystic kidneys. ES-sulfate incorporation into these cultures
showed increased labeling in 220 Kd and 175 Kd protein bands,
as compared to normal cultures [43]. However, short-term
labeling with 35S-methionine followed by immunoprecipitation
showed that there were no differences in core PG protein
synthesis [9]. These results suggest, therefore, that the base-
ment membrane abnormality in the cultured ADPKD cells may
lie in the posttranslational modification of sulfated PGs, or in
their secretion or assembly into basement membrane.
Significance of the basement membrane abnormalities
A number of issues are raised by the evidence of basement
membrane abnormalities in the various animal models and in
human ADPKD. Of importance are the questions of: (1)
whether the primary gene defects in the inherited forms of PKD
are specific for ECM proteins and whether the primary targets
of the cystogenic chemicals or hormones directly affect ECM
synthesis or structure; (2) whether a matrix defect represents an
intrinsic abnormality in cystic cells; and (3) whether there is a
causal relationship between an ECM abnormality and cyst
growth. At present we can only guess at the answers.
Primary?
Until the PKD genes are isolated and identified, there will
remain the possibility that a mutation in an ECM gene causes
PKD. However, a number of basement membrane genes have
now been mapped to chromosomes other than those harboring
PKD, and thus are eliminated from possibility. These would
include a number of collagen, fibronectin, and laminin genes
[44]. In the case of the cystogenic agents, it would be required
that the reactive chemical directly alters ECM structure or that
the hormone directly alters ECM gene expression. It is not
known what the cystogenic chemicals, DPT or NDGA, are
doing at the cellular level to induce cysts. Furthermore, since
corticosteroids are known to have a wide range of effects on
gene expression and cell function at a number of levels in
addition to the basement membrane, it would be difficult to
implicate these hormones as primary cystogens solely at the
level of the ECM; it is very likely that they initiate a cascade of
molecular events, Also of relevence is how soon basement
membrane changes occur in relation to the initiation of cyst
growth. There are examples of early changes in basement
membrane thickening in dilating proximal tubules early in
inherited rodent cystic disease [13]. Furthermore, cyst devel-
opment in the chemical models goes hand-in-hand with base-
ment membrane thickening and alterations in protein composi-
tion [34]. Using the Phenol II derivative of DPT, it was possible
to demonstrate that cystic changes occurred in tandem with
basement membrane alterations and before any significant
increases in 3H-thymidine incorporation into DNA or measur-
able increases in cell division, implicating the basement mem-
brane as the inductive influence leading to subsequent changes
in cell proliferation or morphological transformation [45]. These
studies, however, are limited in their ability to look at molecular
events in the hours immediately following treatment with the
cystogen. In folic acid injury, for example, the renal c-for gene
expression increases shortly after i.p. injection of folic acid and
peaks at three hours [46]. This indicates that kidney cells
respond almost immediately to the chemical and yet do not
enter S phase and begin DNA synthesis until well into the
second day. In fact, one of the early DPT studies reported that
cellular changes, including increases in i..,gh and smooth
endoplasmic reticulum and free polysomes, increased promi-
nence of Golgi complexes, and increased numbers of lyso-
somes, preceded any detectable changes in TBM [33]. The
chemicallhormonal models, because of their rapid cyst induc-
tion, should afford unique systems in which to explore the early
molecular events following treatment with these cystogens.
Intrinsic?
Several lines of evidence support the notion that ECM
abnormalities are, if not primary, at least intrinsic to cystic
cells. Such abnormalities would result from the primary defect
(or chemical insult) indirectly regulating the synthesis, struc-
ture, or assembly of ECM and would be in most cases an
unalterable characteristic of cystic cells. One way to find such
abnormalities is to remove the cells from in vivo controls.
Human ADPKD cells in culture elaborate a highly abnormal
matrix, containing bundles of banded collagen and spherical
aggregates composed in part of sulfated PGs [26]. This would
indicate that these cells retain an abnormal phenotype even
when removed from the kidney and grown for a number of
generations in culture. As indicated above, 35S-sulfate labeling
studies suggested that there are abnormalities in sulfate metab-
olism in cystic cells in culture [9, 12, 42, 43]; however, it should
be recognized that results of such labeling studies are difficult to
interpret unless the labeling of the sulfate pools is addressed
and overall rates of protein synthesis are accounted for. In fact,
as mentioned previously, PG core protein synthesis seemed to
be normal in ADPKD monolayers, despite the pronounced
increase in S incorporation in secreted proteins [9]. A number
of studies have examined proteins secreted from cystic cells
and their normal counterparts in culture. 35S-labeled proteins
from porcine polycystic cells and human ADPKD cells showed
different elution profiles as compared to those from normal
kidneys [12, 47], however, the significance of these differences
remains to be elucidated. Furthermore, it is not clear whether
the differences reflect basement membrane proteoglycans or
represent other sulfated glycoproteins. Another sulfated glyco-
protein known to be overexpressed in cystic kidneys in vivo,
but which has not been linked to the matrix, is SGP-2 (sulfated
glycoprotein-2) [48].
Granot et al [49] showed that human ADPKD cells in culture
secreted three unique 35S-methionine labeled proteins that were
not produced by normal cells. Again, it is not known whether
these are associated with the matrix. Apparently, however, the
same proteins were detected in cultures of multi-passage nor-
mal cells, suggesting that they may be expressed in cells that
progressively dedifferentiate in culture and thus that the
ADPKD cells were less-differentiated to begin with when
initially cultured. Finally, primary cpk mouse cultures showed
somewhat increased, although variable, synthesis of collagen
IV and laminin [25], again suggesting an intrinsic difference
between normal and cystic cells. However, whether this differ-
ence is due to a unique PKD-associated defect or to an altered
differentiated state in vivo was not tested. In studies conducted
in our lab, it was found that primary cpk cultures, as compared
to normal cultures, demonstrated serum-hypersensitive c-fos
proto-oncogene gene expression [50, Note added in proof]. The
fact that similar serum hypersensitivity could be demonstrated
in cultures of normal cells taken from the kidneys of animals
that had been previously treated with folic acid and thus were
regenerating, suggests that the c-fos response, and perhaps the
increased collagen IV and laminin synthesis, may be associated
with the state of differentiation of the cells, rather than with
PKD per Se.
Causal?
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Cell-ECM interactions are known to affect a number of cell
functions including adhesion, differentiation, proliferation, and
gene expression [51]. It is possible, therefore, that an abnormal
matrix structure might alter tubular cell phenotype and stimu-
late cell proliferation, giving rise to cyst formation. It is of
interest that cultured human ADPKD cells were found to grow
rapidly on plastic and to have no absolute requirement for a
matrix, as compared to normal cells [43, 52]. In addition, their
growth rates differed in response to various matrix components,
with 3H-thymidine incorporation into cells grown on type I
collagen > type IV collagen > fibronectin > laminin. While
these differences in growth rates appear to reflect intrinsic
differences between normal and ADPKD cells, this behavior
would seem to be cellular rather than matrix-controlled. Nev-
ertheless, the mere fact that, with either normal or with
ADPKD cells, growth rates can be demonstrated to depend on
matrix composition illustrates the importance of this inductive
interaction. Therefore, while preliminary, these experiments
point to the potential role that cell-matrix interactions may have
in determining the epithelial phenotype in polycystic kidney
disease. More studies of this kind will have to be carried out to
sort out the potentially complex cell-matrix interactions in
polycystic kidneys, in order to determine if an ECM abnormal-
ity or an ECM receptor abnormality triggers cyst formation. It
is envisioned, however, that transgenic mice carrying altered
ECM genes specifically expressed in the kidney will ultimately
have to be constructed to determine whether an abnormal
matrix component can cause cysts in vivo. The fact that renal
cysts are induced in both c-myc and SV4O Large T transgenic
mice [17—19] already points out that other biochemical path-
ways may be more proximal in the process of cystic transfor-
mation.
Cellular changes in PKD
In addition to the matrix abnormalities, there are a number of
cellular changes inherent to the cystic phenotype. For one,
there is increased cell proliferation [7, 10]. This is most evident
from gross inspection of polycystic kidneys, since tubules
which are only a few cells in circumference grow to reach a size
of millimeters to centimeters in diameter [1, 2]. Microscopic
examination has confirmed that the cyst wall epithelium con-
tains large numbers of cells [53]. Increased cell proliferation has
also been documented by using methods that measure the rate
of cell division [13]. This increased rate of cell division need not
in fact be very rapid since most cysts grow over relatively long
periods of time [1, 2, 7]. Nevertheless, some types of PKD can
give rise to the formation of hyperplastic nodules [54] and even
adenomas and adenocarcinomas [6]. A number of changes in
growth factor expression and responsiveness have been seen in
PKD [55—58], which may be consistent with the increased cell
proliferation. The c-myc and SV4O Large T transgenic mice
Fig. 2. Elevated proto-oncogene expression in C57BL/6J-cpk mouse
kidneys. Northern blots of poly(AY RNA showing c-myc (myc) and
c-fos (los) mRNA levels in normal (NL) and cystic (CY) kidneys from
2-week-old and 3-week-old mice. Note the high level of expression of
c-myc and c-fos mRNA at 2 weeks and especially at 3 weeks. HeLa cell
RNA was also blotted as a positive control for c-myc. Data furnished by
Dr. B.D. Cowley. (Reprinted with permission from Advances in Urol-
ogy 3:53—69, 1990 110].)
[17—19] provide evidence that PKD may be primarily a prolif-
erative disorder.
Cyst growth also requires epithelial fluid secretion [7, 10]. In
fact, while many cysts retain their afferent and efferent tubular
connections and thus can fill by glomerular filtration, an exam-
ination of human ADPKD kidneys has shown that most cysts
have lost their tubular connections [53]. These, then, would
have to fill exclusively by transepithelial fluid secretion. A
number of in vitro cyst model systems have been developed to
examine the basic requirements for the initiation and expansion
of cysts. These make use of primary or immortalized kidney
cells grown in hydrated type I collagen gels. Such culture
systems have shown that a key factor in cyst growth and
expansion is activation of the cAMP signal transduction system
and the resulting stimulation of fluid secretion [27, 59, 60].
Cysts have also been reported to have a reversal of NaK-
ATPase polarity [61, 62]. The mislocated sodium pump may
contribute to the formation of cysts by promoting net fluid
secretion from the basolateral to the apical side of the cystic
epithelium driving fluid into the lumen to cause cyst expansion.
This idea is supported by the observation that treatment of in
vitro cysts with ouabain, which inhibits the sodium pump,
slows cyst enlargement [63, 64]. Thus, cyst formation seems to
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Differentiation
require both cell proliferation for cyst growth and transepithe-
ha! fluid secretion to swell the cyst cavity.
Cell differentiation in polycystic kidneys
Cystic epithelial cells are often morphologically undefined,
suggesting that they have lost some of their differentiated
functions. In studies with the cpk mouse, we have shown that a
number of developmentally regulated genes are abnormally
expressed in PKD. The expression of the proto-oncogenes
c-fos, c-myc, and c-Ki-ras is elevated early in the disease and
becomes markedly raised during the most severe stage of cyst
development (Fig. 2) [65—67]. Furthermore, the elevated c-los
expression in vivo is reflected by hypersensitivity to serum-
stimulation in vitro, indicating that a basic change has taken
place in cystic cells in vivo which persists in cell culture [50,
Note added in proof]. These abnormally high steady-state levels
of proto-oncogene mRNA in cystic kidneys may be due to cells
that are locked in an intermediate stage of differentiation, and
the increasing proto-oncogene expression with advancing dis-
ease may be caused by the recruitment of increasing numbers of
cells into this less-differentiated state.
We have also observed that two developmentally expressed
genes, SGP-2 and preproEGF, are abnormally regulated in
cystic kidneys [48, 55]. The SGP-2 gene is normally expressed
early in development in the condensing nephrogenic mesen-
chyme and is subsequently down-regulated in the maturing
glomeruhi, proximal tubules and collecting ducts; cystic kidneys
continue to synthesize high levels of SGP-2 mRNA, indicating
that these tissues may not be fully differentiated [48]. The
preproEGF gene, which is normally activated during postnatal
kidney maturation, is essentially inactive in cystic kidneys [55].
In addition, EGF may be a renal maturation factor, having been
shown to induce changes indicative of terminal differentiation in
vitro [68], and, by its absence in cpk cystic kidneys, may
actually further contribute to a delay in collecting duct differ-
entiation [55].
Based on these results, we have proposed [Rankin et a!,
manuscript submitted for publication] that expression of the
cystic defect results in cells that are unable to terminally
differentiate. Cyst formation would also result from cellular
injury in a genetically predisposed cystic setting, or in normal
kidneys following exposure to cystogenic chemicals or hor-
mones. In these cases, cells would partially dedifferentiate and
then become locked in an intermediate state of differentiation,
similar to that produced by injury [46, 69]. Acute renal injury is
known to result in the loss of a number of differentiated
characteristics. Ischemic injury, for example, has been shown
to cause partial dedifferentiation of proximal tubule cells,
Fig. 3. Possible interrelationships between
Cell proliferation differentiation, proliferation, and basement
membrane.
resulting in changes in the apical brush border and loss of
epithelial polarization. This is shown by the redistribution of
membrane lipids, NaK-ATPase, PTH-stimulatable adenylate
cyclase, leucine aminopeptidase, and Na-dependent glucose
transport, all of which are characteristic of immature proximal
tubules [70—72]. Following injury-induced dedifferentiation, the
normal kidney would complete the regeneration cycle and
return to a state of terminal differentiation [46, 69], whereas the
polycystic kidney would persist in an immature state, allowing
continued cell proliferation, aberrant tubulogenesis, and ulti-
mately cyst formation. The mislocated NaK-ATPase in cystic
epithelial cells, normally located on the basolatera! side of
polarized, fully-differentiated epithelial cells, is found on the
apical side of collecting duct cysts, a location that is character-
istic of a less-mature state [61]. Finally, cultured cpk cystic
epithelial cells have been shown to synthesize higher levels of
collagen IV and laminin than normal cells [25], a characteristic
of tubules at an earlier stage of development [73] and therefore
an observation that is consistent with a change in differentiated
state.
Conclusion
There is ample evidence that the ECM regulates cell function.
The growth and differentiation of many cell types depends on
adhesive interactions with the ECM, which in turn transduce
signals to the nucleus (Fig. 3). However, the case has not yet
been made for a primary role of the matrix in PKD. Although
there is clear evidence of basement membrane changes, there is
little uniformity in the observations, suggesting that several
different ECM abnormalities would have to be responsible for
cystic change. Indeed, this could be possible if it is considered
that there are a number of different cystic diseases—the domi-
nant and recessive genetic forms of PKD and the chemical
models. It is equally plausible, however, that the primary
lesions (genetic or chemical) first affect a process that controls
the differentiated state of tubular epithelial cells (Fig. 3), which
then alters ECM expression. Whatever the primary cause,
however, it seems that the cystic phenotype, including the
ECM changes, can best be explained in the context of an altered
differentiated state of cystic epithehium.
Note added in proof
RANKIN CA, GRANTHAM JJ, CALVET JP: c-los expression is hyper-
sensitive to serum-stimulation in cultured cystic kidney cells from the
C57BL/6J-cpk mouse. J Cell Physiol 152:578—586, 1992
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